Shahrokh  Shabahang net worth and biography

Shahrokh Shabahang Biography and Net Worth

Insider of Aditxt
Shahrokh Shabahang, MS, Ph.D. Dr. Shabahang has been our Chief Innovation Officer and Director since our inception. In 2009, Dr. Shabahang co-founded Sekris Biomedical Inc. to incubate immunotherapy technologies. He served as its Chairman of the board and Chief Executive Officer since its inception. In 2004, Dr. Shabahang joined Genelux Corporation to lead its clinical development program and to serve as board secretary. Genelux developed an oncolytic virus technology for treatment of cancer, co-invented by Dr. Shabahang. During his tenure from 2004-2007, Genelux raised $20M+ and obtained regulatory approval to initiate First-In-Human clinical studies in Europe with patients who had not responded to chemotherapy. In 2001, Dr. Shabahang became the Director of the Microbiology and Molecular Biology Lab at Loma Linda University (“LLU”). He led the research and development of an antimicrobial therapeutic agent for treatment of dental infections, which was licensed and marketed by one of the largest dental distribution companies. Dr. Shabahang attended the University of California, Santa Barbara from 1982 to 1984 and later received his DDS from the University of Pacific in 1987. He earned his PhD in Microbiology and Molecular Genetics at LLU in 2001. During the same year, he established his laboratory at LLU to study infectious diseases and host immune responses. We believe that Dr. Shabahang’s experience leading biotech startups, leading clinical development programs, and his expertise in immunology and immune tolerance qualifies him to serve as a director of our Company. 

How old is Shahrokh Shabahang?

Dr. Shabahang is currently 61 years old. There are 4 older executives and no younger executives at Aditxt. Learn More on Shahrokh Shabahang's age.

How do I contact Shahrokh Shabahang?

The corporate mailing address for Dr. Shabahang and other Aditxt executives is 2569 WYANDOTTE ST. SUITE 101, MOUNTAIN CA, 94043. Aditxt can also be reached via phone at 650-870-1200 and via email at [email protected]. Learn More on Shahrokh Shabahang's contact information.

Has Shahrokh Shabahang been buying or selling shares of Aditxt?

Shahrokh Shabahang has not been actively trading shares of Aditxt during the last ninety days. Most recently, on Tuesday, June 1st, Shahrokh Shabahang bought 12 shares of Aditxt stock. The stock was acquired at an average cost of $117.20 per share, with a total value of $1,406.40. Learn More on Shahrokh Shabahang's trading history.

Who are Aditxt's active insiders?

Aditxt's insider roster includes Thomas Farley (Insider), Corinne Pankovcin (CFO), and Shahrokh Shabahang (Insider). Learn More on Aditxt's active insiders.

Are insiders buying or selling shares of Aditxt?

During the last twelve months, insiders at the sold shares 1 times. They sold a total of 20,800 shares worth more than $691,184.00. The most recent insider tranaction occured on September, 7th when Major Shareholder Paribas Securities Corp Bnp sold 20,800 shares worth more than $691,184.00. Insiders at Aditxt own 1.2% of the company. Learn More about insider trades at Aditxt.

Information on this page was last updated on 9/7/2023.

Shahrokh Shabahang Insider Trading History at Aditxt

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/1/2021Buy12$117.20$1,406.40View SEC Filing Icon  
See Full Table

Shahrokh Shabahang Buying and Selling Activity at Aditxt

This chart shows Shahrokh Shabahang's buying and selling at Aditxt by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aditxt Company Overview

Aditxt logo
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Read More

Today's Range

Now: $2.22
Low: $2.14
High: $2.40

50 Day Range

MA: $3.31
Low: $2.22
High: $4.00

2 Week Range

Now: $2.22
Low: $2.14
High: $68.08

Volume

62,239 shs

Average Volume

353,931 shs

Market Capitalization

$532,800.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29